CN1266118C - 新的δ－氨基－γ－羟基－ω－芳基－链烷酰胺类化合物 - Google Patents

新的δ－氨基－γ－羟基－ω－芳基－链烷酰胺类化合物 Download PDF

Info

Publication number
CN1266118C
CN1266118C CNB2004100346824A CN200410034682A CN1266118C CN 1266118 C CN1266118 C CN 1266118C CN B2004100346824 A CNB2004100346824 A CN B2004100346824A CN 200410034682 A CN200410034682 A CN 200410034682A CN 1266118 C CN1266118 C CN 1266118C
Authority
CN
China
Prior art keywords
lower alkoxy
alkoxy
alkyl
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004100346824A
Other languages
English (en)
Chinese (zh)
Other versions
CN1550491A (zh
Inventor
R·戈斯克
J·K·迈包姆
W·施林
S·施图兹
P·里戈里埃
Y·山口
N·C·科恩
P·赫罗德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1266118(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1550491A publication Critical patent/CN1550491A/zh
Application granted granted Critical
Publication of CN1266118C publication Critical patent/CN1266118C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CNB2004100346824A 1994-04-18 1995-04-17 新的δ－氨基－γ－羟基－ω－芳基－链烷酰胺类化合物 Expired - Lifetime CN1266118C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18
CH1169/1994 1994-04-18
CH1169/94 1994-04-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB951050370A Division CN1153759C (zh) 1994-04-18 1995-04-17 新的δ-氨基-γ羟基-ω-芳基-链烷酰胺类化合物

Publications (2)

Publication Number Publication Date
CN1550491A CN1550491A (zh) 2004-12-01
CN1266118C true CN1266118C (zh) 2006-07-26

Family

ID=4204102

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB951050370A Expired - Lifetime CN1153759C (zh) 1994-04-18 1995-04-17 新的δ-氨基-γ羟基-ω-芳基-链烷酰胺类化合物
CNB2004100346824A Expired - Lifetime CN1266118C (zh) 1994-04-18 1995-04-17 新的δ－氨基－γ－羟基－ω－芳基－链烷酰胺类化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB951050370A Expired - Lifetime CN1153759C (zh) 1994-04-18 1995-04-17 新的δ-氨基-γ羟基-ω-芳基-链烷酰胺类化合物

Country Status (26)

Country Link
US (5) US5559111A (en_2)
EP (1) EP0678503B1 (en_2)
JP (1) JP3240322B2 (en_2)
KR (1) KR100353779B1 (en_2)
CN (2) CN1153759C (en_2)
AT (1) ATE183997T1 (en_2)
AU (1) AU699616B2 (en_2)
BR (1) BR1100656A (en_2)
CA (1) CA2147056C (en_2)
CY (4) CY2208B1 (en_2)
CZ (1) CZ287935B6 (en_2)
DE (4) DE59506707D1 (en_2)
DK (1) DK0678503T3 (en_2)
ES (1) ES2137478T3 (en_2)
FI (1) FI118336B (en_2)
GR (1) GR3031997T3 (en_2)
HU (2) HU226860B1 (en_2)
IL (1) IL113403A (en_2)
LU (2) LU91373I2 (en_2)
MY (1) MY119161A (en_2)
NL (2) NL300296I2 (en_2)
NO (4) NO310410B1 (en_2)
NZ (1) NZ270936A (en_2)
RU (1) RU95105970A (en_2)
TW (2) TW366341B (en_2)
ZA (3) ZA953051B (en_2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241650A (zh) * 2010-05-14 2011-11-16 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
CN1210268C (zh) * 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
DE50006271D1 (de) * 1999-07-29 2004-06-03 Speedel Pharma Ag Basel 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung
BR0112128A (pt) * 2000-07-03 2003-05-13 Speedel Pharma Ag Processo para a preparação de (r)-2-alquil-3-fenil-1-propanóis
KR100690471B1 (ko) * 2000-07-05 2007-03-09 스페델 파르마 아게 치환된 옥타노일 아미드의 제조방법
EP1303478B1 (en) * 2000-07-25 2004-05-26 Speedel Pharma AG Process for the preparation of substituted octanoyl amides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1215201E (pt) * 2000-12-14 2007-02-28 Speedel Pharma Ag Processo para a preparação de ariloctanoil amidas
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
CN1279178C (zh) 2001-05-15 2006-10-11 斯皮德尔药品公司 通过酶水解制备取代羧酸酯的方法
CA2450557A1 (en) * 2001-06-11 2002-12-19 Michel Maillard Substituted aminoalcohols useful in treatment of alzheimer's disease
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
WO2003103652A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
AU2003238007A1 (en) * 2002-06-11 2003-12-22 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
AU2003288899B2 (en) * 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
WO2004050609A1 (en) 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MXPA06002188A (es) * 2003-08-25 2006-04-27 Warner Lambert Co Nuevos compuestos antimicrobianos de ariloxazolidinona.
RU2413716C2 (ru) * 2003-11-26 2011-03-10 Новартис Аг АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
AU2005205914A1 (en) * 2004-01-22 2005-08-04 Novartis Ag Combination of organic compounds
BRPI0507067A (pt) * 2004-01-23 2007-06-12 Speedel Experimenta Ag diamino álcoois e seu uso como inibidores de renina
WO2005070871A2 (en) * 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
KR20070006774A (ko) 2004-03-17 2007-01-11 노파르티스 아게 치료에서 레닌 억제제의 용도
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
EP1725530A1 (en) * 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
CN1934083A (zh) * 2004-03-19 2007-03-21 斯皮德尔实验股份公司 作为肾素抑制剂用于治疗高血压的5－氨基－4－羟基－7－(1h－吲哚基甲基)－8－甲基壬酰胺衍生物
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds
RU2407523C2 (ru) 2004-10-08 2010-12-27 Новартис Аг Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
US20080293701A1 (en) * 2005-02-02 2008-11-27 Baldwin John J 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
BRPI0609158A2 (pt) * 2005-03-11 2010-02-23 Speedel Experimenta Ag alcanamidas substituìdas heterocìclicas úteis como inibidores de renina
PT1861352E (pt) * 2005-03-17 2009-12-21 Basf Se Processo para a preparação de derivados de ácido 3- fenilpropiónico opticamente activos e respectivos produtos secundários
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
WO2007006532A1 (en) 2005-07-11 2007-01-18 Novartis Ag New pyrocatechin derivatives
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
AU2006272348B2 (en) 2005-07-22 2011-06-16 Merck Frosst Canada Ltd Renin inhibitors
CA2622082A1 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
EP1937248B1 (en) * 2005-09-17 2010-06-02 Novartis Ag Alcanoic acid amides substituted by saturated o-heterocycles
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
GB0519764D0 (en) * 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
US20080274171A1 (en) * 2005-10-18 2008-11-06 Nicoletta Almirante Renin Inhibitors Nitroderivatives
EP1940374A2 (en) 2005-10-21 2008-07-09 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
US20100298328A1 (en) * 2006-03-31 2010-11-25 Vitae Pharmaceuticals, Inc 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
WO2007118023A1 (en) * 2006-04-03 2007-10-18 Novartis Ag Renin inhibitors for the treatment of hypertension
TW200815324A (en) * 2006-06-23 2008-04-01 Daiichi Sankyo Co Ltd Straight chain amine compound
ATE549322T1 (de) 2006-06-23 2012-03-15 Daiichi Sankyo Co Ltd Cyclische aminverbindung
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
HRP20140183T1 (hr) 2006-07-20 2014-04-11 Novartis Ag Derivati amino-piperidina kao cetp-inhibitori
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
KR20090083918A (ko) * 2006-11-07 2009-08-04 노파르티스 아게 알리스키렌 헤미푸마레이트의 결정질 형태
EP2089356B1 (en) * 2006-11-09 2012-04-25 Novartis AG Salt of aliskiren with orotic acid
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
AR065792A1 (es) * 2007-03-21 2009-07-01 Speedel Experimenta Ag Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AU2008234834B2 (en) * 2007-04-03 2012-01-19 Novartis Ag New methods
WO2009007461A1 (en) * 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
WO2009040373A2 (en) 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of aliskiren
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
MX2010004929A (es) 2007-11-05 2010-05-27 Novartis Ag Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
BRPI0822652A2 (pt) 2007-11-13 2015-06-23 Teva Pharmáceutica Ind Ltd Petach Tirva 49131 Fórmulas polimórficas de hemifumarato de alisquireno e processos para a sua preparação
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
ES2375527T3 (es) 2007-12-03 2012-03-01 Novartis Ag Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
CN102036948A (zh) * 2008-05-23 2011-04-27 特瓦制药工业有限公司 阿利吉仑单富马酸盐及其制备方法
CN102143939A (zh) * 2008-06-06 2011-08-03 特瓦制药工业有限公司 阿利吉仑游离碱的固体形式
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
WO2010086312A1 (en) 2009-01-28 2010-08-05 Novartis Ag Galenic formulations of organic compounds
CA2724152A1 (en) * 2009-02-05 2010-08-12 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
KR20110129482A (ko) 2009-03-20 2011-12-01 노파르티스 아게 알리스키렌을 포함하는 제약 조성물
CN102348452A (zh) 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
CA2757056A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20130005730A1 (en) * 2009-11-09 2013-01-03 Piaoyang Sun Novel 1,3-oxazolidine compounds and their use as renin inhibitors
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
WO2011098258A1 (en) * 2010-02-10 2011-08-18 Ratiopharm Gmbh Salts of aliskiren
AR080683A1 (es) 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
EP2382969A1 (en) 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
ES2528701T3 (es) 2010-10-19 2015-02-11 Mylan Laboratories Limited Síntesis de Aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
US9056816B2 (en) 2011-10-25 2015-06-16 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
WO2013121443A1 (en) 2012-02-17 2013-08-22 Mylan Laboratories Ltd. An improved process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
AU2013258001A1 (en) 2012-05-11 2014-10-30 Novartis Ag Dispensing device
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
CA2914899C (en) * 2013-06-27 2022-08-30 Dpx Holdings B.V. Preparation of grignard reagents using a fluidized bed
JP2021528735A (ja) 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241650A (zh) * 2010-05-14 2011-11-16 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用

Also Published As

Publication number Publication date
CY2007027I1 (el) 2009-11-04
US5654445A (en) 1997-08-05
HUT74074A (en) 1996-10-28
DE122007000071I1 (de) 2008-01-31
NO2009011I2 (no) 2010-11-22
EP0678503B1 (de) 1999-09-01
MY119161A (en) 2005-04-30
CY2208B1 (en) 2002-11-08
FI951771A0 (fi) 1995-04-12
LU91373I2 (fr) 2007-12-31
FI118336B (fi) 2007-10-15
CA2147056C (en) 2005-10-25
DK0678503T3 (da) 2000-03-20
CA2147056A1 (en) 1995-10-19
CY2009006I2 (el) 2010-07-28
DE122007000071I2 (de) 2009-01-02
CZ287935B6 (cs) 2001-03-14
JP3240322B2 (ja) 2001-12-17
NO2007011I2 (en_2) 2011-07-25
ZA953052B (en) 1995-10-18
NL300386I1 (nl) 2009-07-01
HK1070881A1 (en) 2005-06-30
HU226860B1 (en) 2009-12-28
TW402582B (en) 2000-08-21
ZA953050B (en) 1995-11-08
CY2007027I2 (el) 2009-11-04
HU9501078D0 (en) 1995-06-28
NO951441L (no) 1995-10-19
ATE183997T1 (de) 1999-09-15
RU95105970A (ru) 1997-01-10
CY2009006I1 (el) 2010-07-28
US5646143A (en) 1997-07-08
CN1550491A (zh) 2004-12-01
NL300296I2 (nl) 2008-02-01
NO310410B1 (no) 2001-07-02
IL113403A (en) 2001-07-24
KR950032037A (ko) 1995-12-20
TW366341B (en) 1999-08-11
BR1100656A (pt) 2000-06-06
NZ270936A (en) 1997-06-24
NO2011020I1 (no) 2011-09-26
DE59506707D1 (de) 1999-10-07
GR3031997T3 (en) 2000-03-31
ES2137478T3 (es) 1999-12-16
EP0678503A1 (de) 1995-10-25
FI951771A7 (fi) 1995-10-19
DE122011100052I1 (de) 2012-01-19
NO951441D0 (no) 1995-04-12
IL113403A0 (en) 1995-07-31
US5559111A (en) 1996-09-24
AU699616B2 (en) 1998-12-10
US5705658A (en) 1998-01-06
NL300296I1 (nl) 2007-12-03
KR100353779B1 (ko) 2003-01-08
HU9501076D0 (en) 1995-06-28
CZ97695A3 (en) 1995-11-15
JPH0881430A (ja) 1996-03-26
HUT71701A (en) 1996-01-29
DE122009000020I1 (de) 2009-08-06
CY2011015I2 (el) 2014-04-09
NO2007011I1 (no) 2007-12-11
AU1642195A (en) 1995-10-26
ZA953051B (en) 1995-10-18
US5627182A (en) 1997-05-06
CN1153759C (zh) 2004-06-16
CY2011015I1 (el) 2014-04-09
LU91564I2 (fr) 2009-07-06
CN1117960A (zh) 1996-03-06
NO2009011I1 (no) 2009-06-02

Similar Documents

Publication Publication Date Title
CN1266118C (zh) 新的δ－氨基－γ－羟基－ω－芳基－链烷酰胺类化合物
CN1039321C (zh) 新的β－氨基－α羟基羧酸的制备方法
CN1054598C (zh) 具有药理活性的肼类衍生物及其制备方法
CN1049431C (zh) 吗啉衍生物及其用途和含该衍生物的药物制剂
CN1026892C (zh) 新颖氨基酸衍生物的制备方法
CN1253441C (zh) 蛋白酶抑制剂
CN100338044C (zh) Hiv蛋白酶抑制剂、含有它们的组合物、其药物应用及其合成原料
CN1077886C (zh) 用作一氧化一氮合酶抑制剂的脒基衍生物
CN1105706C (zh) 用作氧化氮合成酶抑制剂的环状脒基制剂
CN1136556A (zh) 芳香族取代的w-氨基链烷酸酰胺和链烷酸二酰胺
CN1169986A (zh) 2,9－二氨基和2－氨基－8－氨基甲酰基－4－羟基－链烷酸酰胺衍生物
CN1328550A (zh) 作为前列腺素e2激动剂或拮抗剂的噁唑化合物
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1085546A (zh) 胺二醇蛋白酶抑制剂
CN1732146A (zh) 钾通道功能的环烷基抑制剂
CN1098409A (zh) α-哌嗪酮及其应用
CN87101499A (zh) 正斯塔提尼及正环斯塔提尼多肽的制备方法
CN1391564A (zh) 化合物
CN1662509A (zh) 可用作激酶抑制剂的吡咯并三嗪苯胺化合物
CN1341592A (zh) 蛋白酶抑制剂
CN1708489A (zh) 1－(4－苄基－哌嗪－1－基)－3－苯基－丙烯酮衍生物
CN1898219A (zh) 作为组织蛋白酶抑制剂的新的酮基噁二唑衍生物
CN1204889C (zh) 粘附受体拮抗剂
CN1512983A (zh) 作为组织蛋白酶s抑制剂的化合物和组合物
CN1145075A (zh) 内皮素受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070881

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20150417

Granted publication date: 20060726